Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

The First Affiliated Hospital of Xiamen University is the lead sponsor of 65 current clinical trials in our China register. 56 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Adebrelimab, Docetaxel and Orelabrutinib. The most-studied condition is PET/CT.

ClinicalTrials.gov trials by status

Recruiting5686%
Not yet open46%
Active, closed35%
By invitation23%

Trials by phase

Phase 22742%
Not applicable1625%
Observational1218%
Phase 146%
Phase 1/223%
Phase 423%
Phase EARLY_PHASE112%
Phase 2/312%

Clinical trials sponsored by The First Affiliated Hospital of Xiamen University

65 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
68Ga-XACP3 PET/CT in Prostate Cancer NCT07242014 · ClinicalTrials.gov ↗ · Prostate Cancer, PET/CT, ACP3	Not applicable	Recruiting	2025-09	China
T-cell Developmental Status in Patients With Malignant Hematological Tumors NCT07035938 · ClinicalTrials.gov ↗ · Hematologic Malignancy	Observational	Recruiting	2025-06	China
Effects of Nonsteroidal Anti-Inflammatory Drugs in Recurrence of Spondyloarthritis Patients After Remission NCT03425812 · ClinicalTrials.gov ↗ · Axial Spondyloarthritis	Not applicable	Recruiting	2018-02	China
Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC NCT07085234 · ClinicalTrials.gov ↗ · Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy	Phase 2	Recruiting	2025-07	China
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma NCT06553352 · ClinicalTrials.gov ↗ · Follicular Lymphoma, Newly Diagnosed Drugs: Obinutuzumab, Zanubrutinib	Phase 2	Recruiting	2024-03	China
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL NCT07778212 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk, First-Line Drugs: Orelabrutinib, Pola-R-Chp	Not applicable	Recruiting	2026-08	China
PET/CT for Trop2 ADC Response Evaluation NSCLC NCT07151898 · ClinicalTrials.gov ↗ · NSCLC, Trop2, PET/CT	Observational	Recruiting	2025-05	China
A Clinical Follow-up Study on the Efficacy of Thumbtack Needle for Postoperative Sleep and Recovery Treatment NCT06757023 · ClinicalTrials.gov ↗ · Postoperative Complications, Postoperative Pain, Acupuncture	Observational	Recruiting	2024-11	China
68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG NCT05873777 · ClinicalTrials.gov ↗ · SSTR2, FAP, Positron-Emission Tomography	Not applicable	Recruiting	2023-04	China
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors NCT06584006 · ClinicalTrials.gov ↗ · Hematological Malignancy, Lymphocytopenia Drug: Thymalfasin	Phase 2	Recruiting	2024-09	China
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL NCT06651853 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma, Relapsed and Refractory	Phase 2	Recruiting	2024-10	China
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) NCT05603884 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute, AML Stage, Adult	Phase 2	Recruiting	2022-12	China
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers NCT06754345 · ClinicalTrials.gov ↗ · Tumor, PD-L1	Observational	Recruiting	2023-05	China
Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease NCT07623382 · ClinicalTrials.gov ↗ · Dry Eye Disease, Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles	Phase EARLY_PHASE1	Recruiting	2026-03	China
A Prospective Nurse Cohort Study in Xiamen, China NCT03799653 · ClinicalTrials.gov ↗ · Hypertension	Observational	Recruiting	2019-03	China
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma NCT05970666 · ClinicalTrials.gov ↗ · Adebrelimab, Hepatocellular Carcinoma, Transformation	Phase 2	Recruiting	2023-11	China
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease NCT07547930 · ClinicalTrials.gov ↗ · Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy Drug: Tofacitinib	Phase 2	Recruiting	2026-04	China
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma NCT07458906 · ClinicalTrials.gov ↗ · DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer	Not applicable	Recruiting	2025-12	China
Pulmonary Vein Isolation (PVI) Combined With Renal Denervation (RDN) in Atrial Fibrillation (AF) and Hypertension (HTN) NCT05841615 · ClinicalTrials.gov ↗ · AF - Atrial Fibrillation, HTN-Hypertension	Not applicable	Recruiting	2023-09	China
GPC3-Targeted PET/CT in Hepatocellular Carcinoma NCT07677774 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT	Not applicable	Recruiting	2026-05	China
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma NCT06826118 · ClinicalTrials.gov ↗ · Lymphoma, Follicular Lymphoma, Refractory Lymphoma Drug: Axicabtagene Ciloleucel	Phase 2	Recruiting	2025-02	China
68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis. NCT06151119 · ClinicalTrials.gov ↗ · Primary Myelofibrosis	Observational	Recruiting	2023-11	China
DLL3-Targeted PET/CT in Small Cell Lung Cancer NCT07677787 · ClinicalTrials.gov ↗ · PET/CT, Small Cell Lung Cancer ( SCLC ), DLL3-targeted PET/CT	Not applicable	Recruiting	2026-05	China
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL NCT06151080 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Drug: Lenalidomide	Phase 2	Recruiting	2023-11	China
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) NCT06387056 · ClinicalTrials.gov ↗ · Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer Drugs: Cisplatin, Docetaxel, Pamiparib	Phase 2	Recruiting	2024-04	China
Comparison of FDG and FAPI in Patients With Various Types of Cancer NCT04416165 · ClinicalTrials.gov ↗ · Tumor, Solid, Positron-Emission Tomography, Metastasis	Not applicable	Recruiting	2019-10	China
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC NCT06811844 · ClinicalTrials.gov ↗ · Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy	Phase 2	Recruiting	2025-02	China
A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer NCT06696326 · ClinicalTrials.gov ↗ · Positron-Emission Tomography(PET), Prostate Cancer, Trophoblast Cell Surface Antigen 2	Not applicable	Recruiting	2024-10	China
the Effect of Transcutaneous Electrical Acupoint Stimulation on Postoperative Gastrointestinal Dysfunction After Urological Laparoscopic Surgery NCT07133620 · ClinicalTrials.gov ↗ · Postoperative Gastrointestinal Dysfunction (POGD)	Not applicable	Recruiting	2025-11	China
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL NCT06875063 · ClinicalTrials.gov ↗ · Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell	Phase 1	Recruiting	2026-04	China
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy NCT06676722 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy Drug: SBRT	Phase 2	Recruiting	2024-11	China
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) NCT03087032 · ClinicalTrials.gov ↗ · Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)	Phase 4	Recruiting	2019-01	China
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children NCT06530004 · ClinicalTrials.gov ↗ · Nephrotic Syndrome, Rituximab, Children Drug: Rituximab	Observational	Recruiting	2020-03	China
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy NCT06478472 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma Drugs: Orelabrutinib, Rituximab	Not applicable	Recruiting	2024-06	China
Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML NCT06737523 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Relapse, Refractory AML	Phase 1	Recruiting	2025-03	China
Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression NCT06375564 · ClinicalTrials.gov ↗ · Refractory Solid Tumor	Phase 1	Recruiting	2024-06	China
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML NCT05305859 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia	Phase 2	Recruiting	2022-01	China
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) NCT06992739 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression	Phase 2	Recruiting	2025-12	China
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL NCT07749365 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma)	Phase 2	Recruiting	2026-07	China
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma NCT07137052 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC), PET / CT	Observational	Recruiting	2025-08	China
PET/CT for Trop2 ADC Response Evaluation Cancers NCT07046689 · ClinicalTrials.gov ↗ · Breast Cancer, Trop2, PET/CT	Observational	Recruiting	2024-11	China
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma NCT06151106 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma	Phase 2	Recruiting	2023-11	China
Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT07783100 · ClinicalTrials.gov ↗ · Relapsed or Refractory Acute Myeloid Leukemia	Phase 2	Recruiting	2026-11	China
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Myelosuppression Drugs: Docetaxel, Trilaciclib	Phase 2	Recruiting	2025-05	China
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma NCT06158386 · ClinicalTrials.gov ↗ · Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Drugs: Chidamide, Linperlisib	Phase 2	Recruiting	2023-11	China
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma NCT06158412 · ClinicalTrials.gov ↗ · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory	Phase 2	Recruiting	2023-11	China
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma NCT06581640 · ClinicalTrials.gov ↗ · Multiple Myeloma, Relapsed/Refractory	Phase 2	Recruiting	2024-09	China
Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients NCT06651866 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 1	Recruiting	2024-12	China
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma NCT06415669 · ClinicalTrials.gov ↗ · Gastric/Gastroesophageal Junction Adenocarcinoma Drugs: Adebrelimab, Apatinib Mesylate, Paclitaxel	Phase 2	Recruiting	2024-05	China
Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients NCT06956144 · ClinicalTrials.gov ↗ · Tumor, Carbonic Anhydrase IX	Observational	Recruiting	2025-05	China
Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML NCT06827899 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	2022-07	China
68Ga-MY6349 PET/CT in Solid Tumors NCT07046702 · ClinicalTrials.gov ↗ · Solid Tumor, Trop2, PET/CT	Observational	Recruiting	2024-12	China
Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer NCT07753499 · ClinicalTrials.gov ↗ · Tumor, Solid Tumor, Thyroid Cancer	Not applicable	Recruiting	2026-08	China
AZA Combined With RCHOP in P53-mutated DLBCL. NCT06158399 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma, TP53	Phase 2	Recruiting	2023-11	China
Graves' Disease Remission Study: MycoMeth Combo NCT06068179 · ClinicalTrials.gov ↗ · Graves' Disease	Phase 2/3	Recruiting	2023-10	China
Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery NCT06282224 · ClinicalTrials.gov ↗ · Pituitary Neoplasms	Not applicable	Recruiting	2024-01	China
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer NCT07031154 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Adebrelimab, Apatinib Drugs: Adebrelimab, Apatinib	Phase 2	Not yet open	2025-06	China
The Effect of Semaglutide on Bone Health NCT07165158 · ClinicalTrials.gov ↗ · Osteoporosis, Osteoporosis Fracture, T2DM Drugs: Metformin, Semaglutide	Phase 4	Not yet open	2025-09	China
Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors NCT07438093 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: Peginterferon α-2b	Not applicable	Not yet open	2026-04	China
Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen NCT07137039 · ClinicalTrials.gov ↗ · Locally Advanced Hypopharyngeal Cancer	Phase 2	Not yet open	2025-08	China
Ultrasound Assessment of Fetal Growth Parameters NCT07018362 · ClinicalTrials.gov ↗ · Fetal Clavicle Length, Fetal Scapular Width, Fetal Sternal Length	Observational	By invitation	2025-07	China
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma NCT06688175 · ClinicalTrials.gov ↗ · Nasopharyngeal Neoplasms, Elderly, Chemotherapy Drug: IMRT	Phase 2	By invitation	2024-11	China
Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation NCT07034950 · ClinicalTrials.gov ↗ · Hepatic Neoplasm, Hepatic Cancer Drug: The of esketamine ED95	Phase 1/2	Active, closed	2025-06	China
Time Restricted Eating on Impaired Glucose Regulation(TRIG Trial) NCT03802253 · ClinicalTrials.gov ↗ · Impaired Glucose Regulation, Overweight/Obese, Time-restricted Eating	Not applicable	Active, closed	2020-05	China
Study on the Effective Dose and Safety of Esketamine in Hysteroscopic Surgery Under Monitored Anesthesia Care NCT07034963 · ClinicalTrials.gov ↗ · Intrauterine Polyp, Intrauterine Synechiae Drug: The of esketamine ED95	Phase 1/2	Active, closed	2025-06	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in The First Affiliated Hospital of Xiamen University trials

27 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in The First Affiliated Hospital of Xiamen University trials

124 conditions

PET/CT5 Follicular Lymphoma4 DLBCL - Diffuse Large B Cell Lymphoma4Trop23Tumor3 Acute Myeloid Leukemia3 Prostate Cancer2 Immunotherapy2Induction Therapy2Positron-Emission Tomography2 Non-Small Cell Lung Cancer2Adebrelimab2Leukemia, Myeloid, Acute2Nasopharyngeal Neoplasms2PET / CT2Refractory Lymphoma2Myelosuppression2Solid Tumor2ACP31Hematologic Malignancy1Axial Spondyloarthritis1Locally Advanced Nasopharyngeal Carcinoma1Newly Diagnosed1Fetal Clavicle Length1

By trial register

Register	Trials	Recruiting
Clinical trials in China	65	56

A trial with sites in more than one country appears in each of those registers.

Other sponsors in PET/CT

Sponsor	Trials
Zhongnan Hospital	4

Sponsors with the most current trials registered for this condition.

Questions about The First Affiliated Hospital of Xiamen University trials

How many clinical trials does The First Affiliated Hospital of Xiamen University sponsor?

The First Affiliated Hospital of Xiamen University is the lead sponsor of 65 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are The First Affiliated Hospital of Xiamen University trials recruiting?

Yes. 56 of its 65 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is The First Affiliated Hospital of Xiamen University testing?

Its current trials name 27 drugs and biologicals as interventions. The most frequent are Adebrelimab (2), Docetaxel (2), Orelabrutinib (2), Rituximab (2) and The of esketamine ED95 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

The First Affiliated Hospital of Xiamen University clinical trials